Bruker (BRKR) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bruker (BRKR) has outperformed Penumbra (PEN) over the past year, gaining 72.8% versus a gain of 27.0%. Over five years, PEN leads with a +18.2% price change compared with -22.7% for BRKR. Penumbra is the larger company by market cap ($12.47 billion vs $8.77 billion), about 1.4 times the size.
On valuation, Bruker trades at a lower forward P/E (23.9x vs 51.6x for Penumbra). Bruker pays a dividend yielding 0.35%, while Penumbra does not currently pay one. Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus -0.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRKR | PEN |
|---|---|---|
| Share price | $57.55 | $316.70 |
| Market cap | $8.77B | $12.47B |
| 1-day change | -3.63% | +0.11% |
| YTD return | +26.77% | +1.75% |
| 1-year return | +72.80% | +27.03% |
| 5-year return | -22.67% | +18.15% |
| P/E ratio (TTM) | — | 77.81 |
| Forward P/E | 23.86 | 51.65 |
| EPS (TTM) | $-0.70 | $4.07 |
| Dividend yield | 0.35% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $3.44B | $1.40B |
| Revenue growth (YoY) | +2.08% | +17.50% |
| Net income (latest FY) | $-8.60M | $177.69M |
| Gross margin | 45.91% | 67.14% |
| Operating margin | 1.98% | 13.48% |
| Net margin | -0.25% | 12.66% |
| 52-week high | $66.98 | $362.41 |
| 52-week low | $32.37 | $221.26 |
| Distance from 52-week high | -14.08% | -12.61% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +9.90% | +14.17% |
| Average volume | 2.23M | 344.71K |
| Shares outstanding | 152.36M | 39.39M |
| Employees | 11,085 | 4,700 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BRKR has outperformed PEN by 45.8 percentage points over the past year.
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus -0.3 cents for Bruker.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +2.08%).
- The two companies sit in different sectors: Bruker in Industrials and Penumbra in Health Care.
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
BRKR vs PEN FAQ
Which is bigger, Bruker or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.47B compared with $8.77B for Bruker (BRKR).
Which stock has performed better over the past year, BRKR or PEN?
BRKR returned +72.80% over the past 12 months, compared with +27.03% for PEN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bruker or Penumbra?
Bruker pays a dividend yielding 0.35%, while Penumbra does not currently pay a regular dividend.
Are Bruker and Penumbra in the same industry?
No. Bruker is in the Industrials sector, while Penumbra is in Health Care.